Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 11, 2010, Pages 1308-1315

  Van Vlerken, Lotte G ^a   Van Soest, Hanneke ^a   Janssen, Mart P ^a   Boland, Greet J ^a   Drenth, Joost P H ^b   Burger, David M ^b   Siersema, Peter D ^a   Van Erpecum, Karel J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

anaemia; antiviral therapy; erythropoietic growth factors; erythropoietin; hepatitis C; ribavirin

Indexed keywords

AMANTADINE; CREATININE; ERYTHROPOIETIN; HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG RESPONSE; FEMALE; GRANULOCYTOPENIA; HEMATOCRIT; HEPATITIS C; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANEMIA; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CREATININE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; FEMALE; HEMATOCRIT; HEMOGLOBINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 78049292784     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32833e784d     Document Type: Article

References (32)

1. Fried MW, Shiffman ML, Reddy K.R., Smith C., Marinos G, Goncales FL, et al Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
2. Manns MP, McHutchison JG, Gordon S.C., Rustgi VK, Shiffman M, Reindollar R, et al Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
3. Bodenheimer HC J.r., Lindsay KL, Davis G.L., Lewis JH, Thung SN, Seeff LB Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26:473-477.
4. Canonico PG, Kastello MD, Cosgriff T.M., Donovan JC, Ross PE, Spears CT, et al Hematological and bone marrow effects of ribavirin in rhesus monkeys. Toxicol Appl Pharmacol 1984; 74:163-172.
5. Canonico PG, Kastello MD, Spears C.T., Brown JR, Jackson EA, Jenkins DE Effects of ribavirin on red blood cells. Toxicol Appl Pharmacol 1984; 74:155-162.
6. Ganser A, Carlo-Stella C, Greher J., Volkers B, Hoelzer D. Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 1987; 70:1173-1179.
7. Jelkmann WE, Fandrey J, Frede S., Pagel H. Inhibition of erythropoietin production by cytokines. Implications for the anemia involved in inflammatory states. Ann N Y Acad Sci 1994; 718:300-309.
8. McHutchison JG, Manns M, Patel K., Poynard T, Lindsay KL, Trepo C, et al Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
9. Reddy KR, Shiffman ML, Morgan T.R., Zeuzem S., Hadziyannis S, Hamzeh FM, et al Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5:124-129.
10. Dieterich DT, Wasserman R, Brau N., Hassanein TI, Bini EJ, Bowers PJ, et al Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98:2491-2499.
11. Shiffman ML, Salvatore J, Hubbard S., Price A, Sterling RK, Stravitz R.T., et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46:371-379.
12. Durante Mangoni E., Marrone A, Saviano D., Del Vecchio C, Utili R, Ruggiero G. Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia. Antivir Ther 2003; 8:57-63.
13. Balan V, Schwartz D, Wu G.Y., Muir AJ, Ghalib R, Jackson J, et al Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. Am J Gastroenterol 2005; 100:299-307.
14. Trivedi HS, Trivedi M. Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C. J Clin Gastroenterol 2004; 38:595-598.
15. Erslev AJ. Anemia of chronic renal disease. Arch Intern Med 1970; 126:774-780.
16. Miller CB, Jones RJ, Piantadosi S, Abeloff M.D., Spivak JL Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322:1689-1692.
17. Spivak JL, Barnes DC, Fuchs E, Quinn TC Serum immunoreactive erythropoietin in HIV-infected patients. JAMA 1989; 261:3104-3107.
18. Van Soest H., Van der Schaar PJ, Koek GH, De Vries RA, Van Ooteghem NA, Van Hoek B, et al. No beneficial effects of amantadine in treatment of chronic hepatitis C patients. Dig Liver Dis 2010; 42:496-502.
19. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
20. Bedossa P, Poynard T; The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24:289-293.
21. Erslev AJ, Caro J, Miller O., Silver R. Plasma erythropoietin in health and disease. Ann Clin Lab Sci 1980; 10:250-257.
22. Erslev AJ. Erythropoietin. N Engl J Med 1991; 324:1339-1344.
23. Tobin J. Estimation of relationships for limited dependent variables. Econometrica 1958; 26:24-36.
24. Cox DR, Hinkley DV Theoretical statistics. 1st ed. London: Chapmann and Hall; 1974.
25. Pegasys [peginterferon alfa-2a]. Package insert 2002. Hoffmann-La Roche, Nutley, New Jersey, USA. (http://www.gene.com/gene/products/information/pegasys) .
26. Reau N, Hadziyannis SJ, Messinger D, Fried M.W., Jensen DM Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol 2008; 103:1981-1988.
27. Sulkowski MS, Wasserman R, Brooks L., Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11:243-250.
28. Jen JF, Glue P, Gupta S., Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22:555-565.
29. Hiramatsu N, Kurashige N, Oze T., Takehara T, Tamura S, Kasahara A., et al. Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C. Hepatol Res 2008; 38:52-59.
30. Lindahl K, Schvarcz R, Bruchfeld A., Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004; 11:84-87.
31. Morello J, Rodriguez-Novoa S, Jimenez-Nacher I, Soriano V. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother 2008; 62:1174-1180.
32. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19 (Suppl 1):17-24.